<DOC>
	<DOC>NCT01991340</DOC>
	<brief_summary>This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.</brief_summary>
	<brief_title>H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically confirmed HER2positive breast cancer Eligible to receive Herceptin as per Summary of Product Characteristics Contraindications according to Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>